BAX 326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1-2%) Hemophilia B - A Continuation Study

Trial Profile

BAX 326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1-2%) Hemophilia B - A Continuation Study

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Nonacog gamma (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Sponsors Baxalta; Baxter Healthcare Corporation
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 06 Aug 2017 This study has been completed in Ireland as per European Clinical Trials Database (End date: 29/06/2017).
    • 27 Jul 2017 This study has been completed in Poland as per European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top